Suppression of IL-1β expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells

Biochemical Pharmacology

Volumn 72, Issue 11, 2006, Pages 1555-1562

  Yu, Ji Hoon ^a   Kim, Kyung Hwan ^a   Kim, Hyeyoung ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

AG490; Cerulein; IL 1 ; Jak Stat; Pancreatic acinar cells

Indexed keywords

CERULETIDE; INTERLEUKIN 1BETA; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TYRPHOSTIN; TYRPHOSTIN AG-490;

ACINAR CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; MALE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; PANCREAS; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; CAERULEIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENE EXPRESSION; INTERLEUKIN-1BETA; JANUS KINASE 2; MALE; PANCREAS; PANCREATITIS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 33751041955     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.008     Document Type: Article

References (50)

1. Kingsnorth A. Role of cytokines and their inhibitors in acute pancreatitis. Gut 40 (1997) 1-4
2. Formela L.J., Galloway S.W., and Kingsnorth A.N. Inflammatory mediators in acute pancreatitis. Br J Surg 82 (1995) 6-13
3. Frossard J.L., Hadengue A., and Pastor C.M. New serum markers for the detection of severe acute pancreatitis in humans. Am J Respir Crit Care Med 164 (2001) 162-170
4. Viedma J.A., Perez-Mateo M., Dominguez J.E., and Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 33 (1992) 1264-1267
5. Heath D.I., Cruickshank A., Gudgeon M., Jehanli A., Shenkin A., and Imrie C.W. Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut 34 (1993) 41-45
6. Sameshima H., Ikei S., Mori K., Yamaguchi Y., Egami H., Misumi M., et al. The role of tumor necrosis factor-alpha in the aggravation of cerulein-induced pancreatitis in rats. Int J Pancreatol 14 (1993) 107-115
7. McKay C.J., Gallagher G., Brooks B., Imrie C.W., and Baxter J.N. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. Br J Surg 83 (1996) 919-923
8. Tracey K.J., and Cerami A. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels. Proc Soc Exp Biol Med 200 (1992) 233-239
9. Zamir O., Hasselgren P.O., Kunkel S.L., Frederick J., Higashiguchi T., and Fischer J.E. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg 127 (1992) 170-174
10. Schirmer W.J., Schirmer J.M., and Fry D.E. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 124 (1989) 445-448
11. Kishimoto T., Taga T., and Akira S. Cytokine signal transduction. Cell 76 (1994) 253-262
12. Gorelick F.S., Adler G., and Kerin H.F. Cerulein-induced pancreatitis. In: Go V.W., DiMagno E.P., Gardner J.D., Lebenthal E., Reber H.A., and Scheele G.A. (Eds). The pancreas: biology, pathobiology, and disease. 2nd ed. (1993), Raven Press, New York 501-526
13. Willemer S., Elsasser H.P., and Adler G. Hormone-induced pancreatitis. Eur Surg Res 24 Suppl. 1 (1992) 29-49
14. Jensen R.T., Wank S.A., Rowley W.H., Sato S., and Gardner J.D. Interaction of CCK with pancreatic acinar cells. Trends Pharmacol Sci 10 (1989) 418-423
15. Sato S., Stark H.A., Martinez J., Beaven M.A., Jensen R.T., and Gardner J.D. Receptor occupation, calcium mobilization, and amylase release in pancreatic acini: effect of CCK-JMV-180. Am J Physiol 257 (1989) G202-G209 [Gastrointest Liver Physiol 20]
16. Lerch M.M., and Adler G. Experiemental animal models of acute pancreatitis. Int J Pancreatol 15 (1994) 159-170
17. Yu J.H., Lim J.W., Namkung W., Kim H., and Kim K.H. Suppression of cerulein-induced cytokine expression by antioxidants in pancreatic acinar cells. Lab Inv 82 (2002) 1359-1368
18. Kim H.Y., Seo J.Y., Roh K.W., Lim J.W., and Kim K.W. Suppression of NF-kB activation and cytokine production by N-acetylsysteine in pancreatic acinar cells. Free Radic Biol Med 29 (2000) 674-683
19. Igaz P., Toth S., and Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res 50 (2001) 435-441
20. Kovarik P., Mangold M., Ramsauer K., Heidari H., Steinborn R., Zotter A., et al. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 20 (2001) 91-100
21. Park C., and Schindler C. Protein-DNA interactions in interferon-gamma signaling. Methods 15 (1998) 175-188
22. Wen Z., Zhong Z., and Darnell J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995) 241-250
23. Gazit A., Yaish P., Gilon C., and Levitzki A. Synthesis biological activity of protein tyrosine kinase inhibitors. J Med Chem 32 (1989) 2344-2352
24. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
25. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379 (1996) 645-648
26. Simon H.U., Yousefi S., Dibbert B., Levischaffer F., and Blaser K. Antiapoptitic signals of granulocyte-macrophage colony stimulating factors are transduced via JAK2 tyrosine kinase in eosinophils. Eur J Immunol 27 (1997) 3536-3539
27. Marrero M.B., Schieffer B., Li B., Sun J.M., Harp J.B., and Ling B.N. Role of Janus kinase signal transducer and activator of transcription and mitogenactivated protein kinases cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 272 (1997) 24684-24690
28. McWhinney C.D., Hunt R.A., Conrad K.M., Dostal D.E., and Baker K.M. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through JAK2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol 29 (1997) 2513-2524
29. Nielsen M., Kaltoft M., Nordahl M., Ropke C., Geisler C., Mustelin T., et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG-490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA 94 (1997) 6764-6769
30. Toyonaga T., Nakano K., Nagano M., Zahao G., Yamaguchi K., Kuroki S., et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 201 (2003) 107-116
31. Rahaman S.O., Harbor P.C., Chernova O., Barnett G.H., Vogelbaum M.A., and Haque S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21 (2002) 8404-8413
32. Burke W.M., Jin X., Lin H.J., Huang M., Liu R., Reynolds R.K., et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20 (2001) 7925-7934
33. Burdelya L., Catlett-Falcone R., Levitzki A., Cheng F., Mora L.B., Sotomayor E., et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 1 (2002) 893-899
34. Kuwano Y., Kawahara T., Yamamoto H., Teshima-Kondo S., Tominaga K., Masuda K., et al. Interferon-γactivates transcription of NADPH oxidase 1 gene and upregulates production of superoxide anion by human large intestinal epithelial cells. Am J Physiol Cell Physiol 290 (2006) C433-C443
35. Arany I., Megyesi K., Nelkin B.D., and Safirstein R.L. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 70 (2006) 669-674
36. Higuchi T., Shiraishi T., SHirakusa T., Hirayama S., Shibaguchi H., Kuroki M., et al. Prevention of acute lung allograft rejection in rat by the Janus kinase 3 inhibitor, tyrphostin AG490. J Heart Lung Transplant 24 (2005) 1557-1564
37. Behbod F., Erwin-Cohen R.A., Wang M.-E., Trawick B.W.E., Qu X., Verani R., et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 166 (2001) 3724-3732
38. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidine isothiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
39. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
40. Fu X.Y., Kessler D.S., Veals S.A., Levy D.E., and Darnelle J.E. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci USA 87 (1990) 8555-8559
41. Kessler D.S., Veaks S.A., Fu X.Y., and Leavy D.E. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 4 (1990) 1753-1765
42. Rawlings J.S., Rosler K.M., and Harrison D.A. The JAK/STAT signaling pathway. J Cell Sci 117 (2004) 1281-1283
43. Alexander S.D.H., Mathie A., and Peters J.A. Nomenclature supplement. Trends Pharmacol Sci 22 Suppl. (2001) 1-145
44. Fujimoto M., Igano K., Watanabe K., Irie I., Inouye K., and Okabayashi T. Effects of cerulein-related peptides on CCK receptor bindings in brain and pancreas. Biochem Pharmacol 34 (1985) 1103-1107
45. Huang S.C., Yu D.H., Wank S.A., Mantey S., Gardner J.D., and Jensen R.T. Importance of sulfation of gastrin or cholecystokinin (CCK) on affinity for gastrin and CCK receptors. Peptides 10 (1989) 785-789
46. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., et al. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51 (1999) 745-781
47. Heinemann A., Jocic M., Holzer-Petsche U., Petho G., Peskar B.M., Horwell D.C., et al. Mediation by CCKB receptors of the CCK-evoked hyperaemia in rat gastric mucosa. Br J Pharmacol 116 (1995) 2274-2278
48. Gales C., Kowalski-chauvel A., Dufour M.N., Seva C., Moroder L., Pradayrol L., et al. Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptor. J Biol Chem 275 (2000) 17321-17327
49. Ferrand A., Kowaski-Chauvel A., Bertrand C., Escrieut C., Mathieu A., Portolan G., et al. A novel mechanism for JAK2 activation by a G protein-coupled receptor, the CCK2R. J Biol Chem 280 (2005) 10710-10715
50. Kumano K., Nakao A., Nakajima H., Miike S., Kurasawa K., Saito Y., et al. Blockade of JAK2 by tyrphostin AG-490 inhibits antigen-induced eosinophil recruitment into the mouse airways. Biochem Biophys Res Commun 270 (2000) 209-214